The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory

Mostrar otras versiones (1)

Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against coronavirus disease in 2019 (COVID-19). Clinical trials and ongoing vaccinations present with very high protection levels and varying degrees of side effects. However, the n...

Descripción completa

Detalles Bibliográficos
Autores principales: Ndeupen, Sonia, Qin, Zhen, Jacobsen, Sonya, Estanbouli, Henri, Bouteau, Aurélie, Igyártó, Botond Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941620/
https://www.ncbi.nlm.nih.gov/pubmed/33688649
http://dx.doi.org/10.1101/2021.03.04.430128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941620/
https://www.ncbi.nlm.nih.gov/pubmed/33688649
http://dx.doi.org/10.1101/2021.03.04.430128

Ejemplares similares